Dublin, March 15, 2018 -- The "Global Pediatrics Partnering 2012-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
Global Pediatrics Partnering 2012 to 2018 provides the full collection of Pediatrics disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Pediatrics disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Pediatrics deals.
The report presents financial deal terms values for Pediatrics deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
In addition, a comprehensive appendix is provided with each report of all Pediatrics partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Pediatrics partnering and dealmaking since 2012.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Pediatrics technologies and products.
Report scope
Global Pediatrics Partnering 2012 to 2018 includes:
- Trends in Pediatrics dealmaking in the biopharma industry since 2012
- Analysis of Pediatrics deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Pediatrics deal contract documents
- Comprehensive access to over 3500 Pediatrics deal records
- The leading Pediatrics deals by value since 2012
- Most active Pediatrics dealmakers since 2012
In Global Pediatrics Partnering 2012 to 2018, available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Pediatrics dealmaking
2.1. Introduction
2.2. Pediatrics partnering over the years
2.3. Pediatrics partnering by deal type
2.4. Pediatrics partnering by industry sector
2.5. Pediatrics partnering by stage of development
2.6. Pediatrics partnering by technology type
2.7. Pediatrics partnering by therapeutic indication
Chapter 3 - Financial deal terms for Pediatrics partnering
3.1. Introduction
3.2. Disclosed financials terms for Pediatrics partnering
3.3. Pediatrics partnering headline values
3.4. Pediatrics deal upfront payments
3.5. Pediatrics deal milestone payments
3.6. Pediatrics royalty rates
Chapter 4 - Leading Pediatrics deals and dealmakers
4.1. Introduction
4.2. Most active in Pediatrics partnering
4.3. List of most active dealmakers in Pediatrics
4.4. Top Pediatrics deals by value
Chapter 5 - Pediatrics contract document directory
5.1. Introduction
5.2. Pediatrics partnering deals where contract document available
Chapter 6 - Pediatrics dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Pediatrics therapeutic target
Appendices
Appendix 1 - Directory of Pediatrics deals by company A-Z 2012 to 2018
Appendix 2 - Directory of Pediatrics deals by deal type 2012 to 2018
Appendix 3 - Directory of Pediatrics deals by stage of development 2012 to 2018
Appendix 4 - Directory of Pediatrics deals by technology type 2012 to 2018
For more information about this report visit https://www.researchandmarkets.com/research/h9wh6w/global_pediatrics?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Pharmaceuticals, Pediatrics


Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 



